Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
16 results
  • Head and Neck Cancer, Breast Cancer, Pancreatic Cancer, Sarcoma, Lung Cancer, Ovarian Cancer, Kidney Cancer, Liver Cancer, Thyroid Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Esophageal Cancer, Pancreatic Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Colorectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations

  • Bladder Cancer, Pancreatic Cancer, Liver Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Gastric (Stomach) Cancer, Pancreatic Cancer, Melanoma, Lung Cancer

24-058          Phase II

A Phase 1/2a Study of IMM-6-415 in Participants with Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

  • Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

24-649          Phase I

A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Kidney Cancer, Gastric (Stomach) Cancer, Sarcoma, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Prostate Cancer, Endometrial Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Pancreatic Cancer

22-216          Phase II

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors

Showing 1 - 10 of 16 results